Emergent BioSolutions Inc. Common Stock (NY:EBS)

6.330 -0.040 (-0.63%)

Official Closing Price Updated: 7:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Emergent BioSolutions Inc. Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow ↗

February 20, 2022

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...

Via Benzinga

Johnson & Johnson's COVID-19 Shot Wins Its First Full Approval In Canada ↗

November 24, 2021

Canada has become the first country to fully approve Johnson & Johnson's (NYSE: JNJ) single-dose Covid-19 vaccine. According to a statement, regulators...

Via Benzinga

Why Emergent BioSolutions Popped by Over 4% Today ↗

November 12, 2021

The company has given 250 million reasons why investors should buy its stock.

Via The Motley Fool

The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares ↗

November 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2021 ↗

November 08, 2021

Upgrades For Nektar Therapeutics (NASDAQ:

Via Benzinga

92 Biggest Movers From Friday ↗

November 08, 2021

Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares jumped 99.8% to close at $9.99 on Friday. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the...

Via Benzinga

See Why Emergent BioSolutions Stock Plunged 37% On Friday? ↗

November 05, 2021

After a fiasco surrounding the contamination of COVID-19 vaccine doses in its facilities, Emergent BioSolutions Inc's (NYSE: EBS) manufacturing deal with the US...

Via Benzinga

Mid-Afternoon Market Update: Dow Surges 200 Points; Grid Dynamics Shares Spike Higher ↗

November 05, 2021

Toward the end of trading Friday, the Dow traded up 0.57% to 36,331.86 while the NASDAQ rose 0.20% to 15,972.41. The S&P also rose, gaining 0.40% to 4,698.70. The U.S. has the...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Friday's Intraday Session ↗

November 05, 2021

Gainers Chinook Therapeutics (NASDAQ:KDNY) shares increased by 28.75% to $15.76 during Friday's regular session. Trading volume for this security as of 12:30 EST is 1....

Via Benzinga

Mid-Day Market Update: Gold Rises 1%; Deciphera Pharmaceuticals Shares Plummet ↗

November 05, 2021

Midway through trading Friday, the Dow traded up 0.65% to 36,358.13 while the NASDAQ rose 0.48% to 16,016.51. The S&P also rose, gaining 0.58% to 4,707.33. The U.S. has the...

Via Benzinga

Topics Stocks

64 Stocks Moving In Friday's Mid-Day Session ↗

November 05, 2021

Gainers Mainz Biomed B.V. (NASDAQ: MYNZ) shares climbed 198.4% to $14.92. Mainz Biomed priced its initial public offering of 2 million ordinary shares at $5, the middle of the...

Via Benzinga

Why Emergent Biosolutions Stock Is Crashing Today ↗

November 05, 2021

The U.S. government canceled a contract related to pandemic preparation.

Via The Motley Fool

The Daily Biotech Pulse: NRx's Zyesami Face Regulatory Rejection, Puma Slumps On Q3 Miss, Pfizer Has Good Tidings On Oral Antiviral COVID-19 Pill ↗

November 05, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus NRx's COVID-19 Drug Fails to Get Authorization From FDA Due To...

Via Benzinga

Emergent BioSolutions inc (EBS) Q3 2021 Earnings Call Transcript ↗

November 05, 2021

EBS earnings call for the period ending October 3, 2021.

Via The Motley Fool

Topics Earnings

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

November 04, 2021

Gainers Assertio Holdings (NASDAQ:ASRT) ...

Via Benzinga

Millions Of JNJ COVID-19 Shots Sit Idle At Emergent's Baltimore Plant: Reuters ↗

October 28, 2021

Around 30 million to 50 million doses of Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine manufactured earlier this year sit idle in Emergent BioSolutions...

Via Benzinga

The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO ↗

November 04, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &...

Via Benzinga

The Daily Biotech Pulse: Moderna's Booster Shot Gets FDA Panel Backing, Decision Day For Avadel, Silence Therapeutics Strikes Licensing Deal, MiNK IPO ↗

October 15, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Adcom Recommends Approval Of Moderna's COVID-19 Vaccine Booster Shot For...

Via Benzinga

The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline ↗

October 31, 2021

Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc...

Via Benzinga

5 Value Stocks To Watch In The Healthcare Sector ↗

October 11, 2021

The Meaning Behind Value Stocks A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may...

Via Benzinga

The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO ↗

October 01, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...

Via Benzinga

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug ↗

September 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (...

Via Benzinga

The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug ↗

September 29, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...

Via Benzinga

Shuman, Glenn & Stecker Investigates Emergent BioSolutions, Inc.

September 21, 2021

From Shuman, Glenn & Stecker

Via Business Wire

The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive ↗

September 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (...

Via Benzinga

Emergent Secures Contract To Manufacture Providence Therapeutics' COVID-19 Vaccine Candidate ↗

September 14, 2021

Emergent BioSolutions Inc (NYSE: EBS) has signed a five-year agreement with Providence Therapeutics valued at about $90 million to develop and...

Via Benzinga

Moderna Withdraws 1.6M COVID-19 Vaccine Doses In Japan Over Contamination Concerns ↗

August 26, 2021

More than a million doses of Moderna Inc’s (NASDAQ: MRNA) coronavirus vaccine have been taken out of circulation in Japan after reports of contamination emerged, Nikkei Asia...

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs ↗

September 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Acceleron Pharma Inc. (...

Via Benzinga

Emergent BioSolutions' COVID-19 Plasma Candidate To Be Tested As Outpatient Treatment ↗

August 25, 2021

Emergent BioSolutions Inc (NYSE: EBS) has announced the initiation of a Phase 3 trial that will evaluate its investigational SARS-CoV-2 Immune Globulin Intravenous...

Via Benzinga

NYSE:EBS Long Term Investor Alert: Investigation of Potential Wrongdoing at Emergent BioSolutions Inc ↗

August 23, 2021

San Diego, CA -- (SBWIRE) -- 08/23/2021 -- Certain directors of Emergent BioSolutions Inc are under investigation concerning potential breaches of fiduciary duties.

Via SBWire

Topics Lawsuit

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.